Effect of first‑month specific therapy determines long‑term clinical outcome in patients with pulmonary arterial hypertension
Journal Title: Journal of Rare Cardiovascular Diseases - Year 2018, Vol 3, Issue 6
Abstract
Efficacy of pulmonary arterial hypertension (PAH)-specific therapy may differ among the patients depending on the PAH aetiology. Aim: To compare the real‐life efficacy of PAH‐specific therapy between non‐congenital heart disease (non‐CHD) and CHD groups of PAH patients and to determine whether an early clinical response has an impact on prognosis. Methods: Clinical data from 41 PAH patients, 21 non‐CHD and 20 CHD patients, were included in the study. The WHO functional class (WHO‐FC), 6‐minute walk dis-tance (6MWD) and NT‐proBNP serum level were compared at baseline and after 1 and 7 months of PAH‐specific treatment. Only patients with unmodified PAH‐specific therapy during 7‐month follow‐up were enrolled in the study. Results: Baseline characteristics revealed higher WHO‐FC and increased [log e ]NT‐proBNP levels (7.74 ±1.05 vs 6.51 ±1.48; p = 0.008) in non‐CHD vs. CHD patients; baseline 6MWD was similar in both groups (283.3 ±148.5 m vs 339.2 ±114.7 m). Clinical improvement by at least one WHO‐FC after 1‐month treatment was observed more frequently in non‐CHD (55%) when compared with CHD patients (25%, p = 0.04) and was comparable (50% vs 50%) after 7‐month observation. Non‐CHD patients, who did not improve within 1 month of treatment were unlikely to achieve improvement after 7 months. The 6MWD increased during the first month of treatment in non‐CHD (p=0.009) and in CHD patients (p=0.006) when compared to baseline values and remained at this level after 7 months of treatment. [Log e ]NT‐proBNP levels markedly declined only in non‐CHD patients, who had an improvement in WHO‐FC (8.0 ±1.0 vs 7.4 ±1.1, p = 0.04) in the first month. In CHD patients, the decrease in [log e ]NT‐proBNP level was seen (6.5 ± 1.5 vs 6.1 ±1.5, p = 0.04) only within a 1‐month observation. Conclusion: Efficacy of 1‐month PAH‐specific therapy is aetiology‐dependent and determines clinical outcome in patients with PAH. JRCD 2018; 3 (6): 198–203.
Authors and Affiliations
Adrianna Nowak, Karolina Bula, Karol Głowacki, Wojciech Gawin, Konstantinos Nechoritis, Marek Grabka, Katarzyna Mizia‐Stec
Keywords
Related Articles
- EP ID EP286458
- DOI 10.20418/jrcd.v3i6.316.g223
- Views 100
- Downloads 0
Outcome of pregnancy in patients with bicuspid aortic valve – a study of 89 patients (RCD code: VII-IV-1D.2o)
The changes in hemodynamics, as well as changes in the aortic media during pregnancy, put the women with bicuspid aortic valve (BAV) and significant aortic stenosis (AS) and/or dilated aortic roots at risk for complicati...
Rare diseases and disorders and rare cardiovascular complications
n/a
Establishing a curriculum on rare diseases for medical students
Healthcare workers often have insufficient knowledge on rare diseases that may lead to delay in making a diagnosis and providing appropriate care. The fifth area of the Europlan entitled: “Gathering The Expertise On Rar...
Long QT syndrome diagnosed in the postpartum period (RCD code: VII-V-1A.2)
We report a case of 22 years old woman with long QT syndrome type with the first cardiac incidents in the post partum period. We discuss the actual treatment recommendation in the long QT syndrome with special attention...
Cavernous hemangioma of the heart in a 37‑year‑old male visualized by multislice computed tomography (MSCT) (RCD code: VI‑1B.4)
A 37‑year‑old male with a 6‑month history of atypical nonexertional chest pain and markedly limited exercise capacity was referred for evaluation to our department. He had no previous medical history. There were no patho...